Hyzaar Asia HEAALTH (0954A-950)
- Registration Number
- NCT00354991
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The objective of the study is to estimate the percentage of patients who reach blood pressure goal after 8 weeks of treatment with losartan/HCTZ combination.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 437
Inclusion Criteria
- Patient is male or female and = 18 years of age
- Patients with essential hypertension previously treated with antihypertensive medications for at least 4 weeks but did not reach the blood pressure goal
Exclusion Criteria
- History of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient/subject to participate
- Pregnant or breastfeeding, or expecting to conceive within the projected duration of the study
- Previous history of severe essential hypertension
- History of stroke or myocardial infarction (heart attack)
- Evidence of renal or liver disease
- Uncontrolled diabetes mellitus
- Any known bleeding disorder
- Known sensitivity or intolerance to the study medication (losartan or hydrochlorothiazide)
- Other antihypertensive medications or medications that may affect blood pressure
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 losartan potassium (+) hydrochlorothiazide Losartan/HCTZ
- Primary Outcome Measures
Name Time Method Percentage of patients reaching a blood pressure goal (diastolic <90mm Hg for non-diabetics; <80mm Hg for diabetics) after 8 weeks of treatment 8 Weeks
- Secondary Outcome Measures
Name Time Method Safety and tolerability 13 Weeks